DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zonegran (Zonisamide) - Summary

 
 



ZONEGRAN SUMMARY

ZONEGRAN® (zonisamide) capsules Rx Only

ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents.

ZONEGRAN is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.


See all Zonegran indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Zonegran (Zonisamide)

Trial examines treatment for psychogenic nonepileptic seizures
Source: Anxiety / Stress News From Medical News Today [2014.07.04]
A clinical trial found a reduction in seizures and improvement in related symptoms, including depression and anxiety, in patients with psychogenic nonepileptic seizures (PNES) who were treated with...

Absence epilepsy seizures in mice reduced by neural transplant
Source: Epilepsy News From Medical News Today [2014.06.02]
New research from North Carolina State University pinpoints the areas of the cerebral cortex that are affected in mice with absence epilepsy and shows that transplanting embryonic neural cells into...

New pill developed to suppress epilepsy seizures
Source: Epilepsy News From Medical News Today [2014.05.27]
Drug-resistant epilepsy often requires surgery. Now, a new preventative treatment has been developed that may only require the patient to take a pill at times of seizure risk.

Two Drugs Work Equally Well for Epileptic Seizures in Kids: Study
Source: MedicineNet diazepam Specialty [2014.04.23]
Title: Two Drugs Work Equally Well for Epileptic Seizures in Kids: Study
Category: Health News
Created: 4/22/2014 4:36:00 PM
Last Editorial Review: 4/23/2014 12:00:00 AM

Febrile Seizures
Source: MedicineNet Roseola Specialty [2014.01.15]
Title: Febrile Seizures
Category: Diseases and Conditions
Created: 5/9/2008 12:00:00 AM
Last Editorial Review: 1/15/2014 12:00:00 AM

more news >>

Published Studies Related to Zonegran (Zonisamide)

Zonisamide: its pharmacology, efficacy and safety in clinical trials. [2012]
Zonisamide is a benzisoxazole derivative, chemically unrelated to other antiepileptic drugs, that appears to have multiple mechanisms of action, including inhibition of Na(+) channels and reduction of T-type Ca(2+) currents. It is currently licensed in Europe and the USA for adjunctive treatment of partial seizures in adults, and in Europe as monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy...

Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. [2011.05.17]
CONCLUSIONS: Pooled treatment algorithm results were not significantly different from olanzapine monotherapy in mitigating weight gain. However, participants who received treatment with metformin with possible progression to amantadine and then zonisamide had significantly less mean weight gain than participants treated with olanzapine alone. Progression of some participants through the algorithm indicated that a single therapy solution may not be adequate for every patient. Patients treated with olanzapine should receive regular weight monitoring. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00401973. (c) Copyright 2011 Physicians Postgraduate Press, Inc.

Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial. [2011]
BACKGROUND AND OBJECTIVE: Clinical studies have reported that zonisamide is effective for a wide range of seizure types, including refractory partial-onset seizures. However, there have been no reported studies of the efficacy of zonisamide in the Chinese population to date. The aim of the present study was to evaluate the efficacy and safety of zonisamide in the treatment of adult Chinese patients with refractory partial-onset epilepsy... CONCLUSION: Zonisamide 300-400 mg/day is effective and well tolerated as an adjunctive drug in adult Chinese patients with refractory partial-onset epilepsy.

Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. [2011]
it could be used as an alternative for noncompliant patients to topiramate... CONCLUSION: Our results indicated that zonisamide is as effective as topiramate

Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. [2011]
CONCLUSIONS: In contrast to previous studies that suggested efficacy of

more studies >>

Clinical Trials Related to Zonegran (Zonisamide)

Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial [Active, not recruiting]
The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg

- 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a

body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of weight gain.

Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug [Recruiting]
An open-label, randomized, multi-centre, superiority study to assess that, in patients who respond to zonisamide added as third drug after failure of a two-drug combination therapy, the triple therapy is superior to the conversion to a double therapy including zonisamide.

Fed Study of Zonisamide Capsules 100 mg and ZonegranŽ Capsules 100 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's zonisamide, 100 mg capsules to Elan's ZonegranŽ 100 mg capsules following a single, oral 100 mg (1 x 100 mg) dose administered under fed conditions.

Fasting Study of Zonisamide Capsules 100 mg and ZonegranŽ Capsules 100 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's zonisamide, 100 mg capsules to Elan's ZonegranŽ 100 mg capsules following a single, oral 100 mg (1 x 100 mg) dose administered under fasting conditions.

Zonisamide for Heavy Drinkers With Bipolar Disorder [Recruiting]
This is a randomized, double blind, placebo controlled trial of the medication zonisamide for the purpose of reducing heavy drinking and drinking, as well as reducing mood symptoms, in bipolar subjects that drink excessively and heavily.

Hypotheses: (Primary aims); Add-on zonisamide compared to placebo will result in:

1. significant reduction in heavy drinking days, drinks per week and per drinking day, and significantly greater increase in abstinent days, ii) greater rates of abstinence and abstinence to heavy drinking, greater reduction in biomarkers of heavy alcohol use such as gamma-glutamyl transferase (GGT), and greater reduction in alcohol urge or "craving",

2. Significant reduction in prevalent mood symptoms on the BRMS and BRMeS, CARS, HAMD, or no worsening of euthymic mood, and significant improvement on the Clinical Global Impressions Scale-Severity.

3. (Secondary aims) Add-on zonisamide compared to placebo will result in significant reduction in weight (kilograms) and other secondary weight-related metabolic factors such as fasting glucose, lipid profile, and blood pressure.

4. (Secondary aims) Add-on zonisamide compared to placebo will result in improved clinical global impression, overall functioning, quality of life, and reduced medical symptoms.

5.) (Exploratory Aims) To will examine interactions between genotype and medication on treatment response for allelic variation in genetic loci related to the major neurotransmitter and neurophysiologic pathways that are relevant to bipolar disorder, alcoholism, and zonisamide mechanism of action.

more trials >>

Reports of Suspected Zonegran (Zonisamide) Side Effects

Rash (11)Convulsion (11)Agitation (8)Foetal Exposure During Pregnancy (6)Drug Interaction (6)Fatigue (6)Confusional State (5)Drug Ineffective (5)Chest Pain (5)Vomiting (5)more >>


Page last updated: 2014-07-04

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014